We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Making Single-Cell Biology Work

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

A formal collaboration was announced between the Wellcome Trust Sanger Institute, the European Bioinformatics Institute (EMBL-EBI) and Fluidigm Corporation to accelerate the development of new methods for the analysis of single-cell genomics data.

The Single Cell Genomics Centre (SCGC) on the Wellcome Trust Genome Campus will work with onsite Fluidigm senior staff to ensure that the centre has early access to the latest equipment, workflows and methods for genomics and proteomics research.

"Because we have early access to the most advanced technology, we can develop new experimental and computational methods that help us understand what is happening in each of our cells, at different points in the cell cycle," says Dr Sarah Teichmann of EMBL-EBI and the Sanger Institute. "This is really a new frontier - we hope the work we do will help the technology mature more quickly, so that it can help more people find answers to complex biological questions."

In addition to technology advancements, the collaboration will make single-cell research more accessible to the greater research community by developing and disseminating new workflows, bioinformatics tools, and data sets.

The collaboration builds on previous work between Fluidigm and founding members of the SCGC. For example, the Teichmann group discovered that immune cells produce steroids to regulate themselves - knowledge based on mRNA-seq data from single cells prepared by Fluidigm technology. Using single-cell gene expression data from Fluidigm's C1TM Single-Cell Auto Prep system and sequencing technology, John Marioni's group at EMBL-EBI developed a novel statistical method that shows how single-cell mRNA sequencing can be used to pinpoint true differences between cells in apparently homogeneous samples. Thierry Voet, based at KU Leuven and an associate member of Faculty at the Sanger Institute, uses DNA sequencing at the single-cell level to understand how spontaneous variations in DNA can arise as cells divide.

"Our work with the SCGC is about co-creating a solid foundation for a revolution in biological understanding that will come from single-cell analysis," said Robert C Jones, Fluidigm Executive Vice President of Research and Development. "Together, we can build better informatics tools to extract relevant biology from the massive amounts of single-cell RNA expression data that our systems generate. We'll also find innovative ways to determine the DNA, protein, RNA, and epigenetic state of each cell and to scale the process up to perform across thousands and millions of cells."

These high-throughput techniques allow researchers to explore cellular heterogeneity in normal development and in disease at the single-cell level, offering a vast improvement over the current practice of investigating millions of cells in bulk. Until now, scientists have been limited in their ability to identify functionally distinct subpopulations of cells and understand their contribution into the development of diseases such as cancer. DNA-seq and RNA-seq techniques are opening up new opportunities to discover and explore the diverse nature of cells at the highest possible resolution.